US4839295A
(en)
|
1984-06-08 |
1989-06-13 |
Pierce Chemical Company |
Measurement of protein using bicinchoninic acid
|
DE3639949A1
(de)
|
1986-11-22 |
1988-06-09 |
Diagen Inst Molekularbio |
Verfahren zur trennung von langkettigen nukleinsaeuren
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
CA2033718A1
(en)
|
1990-01-19 |
1991-07-20 |
Ronald M. Atlas |
Process for detection of water-borne microbial pathogens and indicators of human fecal contamination in water samples and kits therefor
|
US5256555A
(en)
|
1991-12-20 |
1993-10-26 |
Ambion, Inc. |
Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
|
WO1995008626A1
(en)
|
1993-09-20 |
1995-03-30 |
The Regents Of The University Of Colorado |
Strategy for the production of rna from immobilized templates
|
CA2468048A1
(en)
|
1994-02-23 |
1995-08-31 |
Pamela Pavco |
Process for purifying chemically synthesized rna
|
JPH083477A
(ja)
|
1994-06-20 |
1996-01-09 |
Nippon Telegr & Teleph Corp <Ntt> |
はっ水性塗料及びその塗装方法
|
US5447922A
(en)
|
1994-08-24 |
1995-09-05 |
Bristol-Myers Squibb Company |
α-phosphonosulfinic squalene synthetase inhibitors
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
US6011148A
(en)
|
1996-08-01 |
2000-01-04 |
Megabios Corporation |
Methods for purifying nucleic acids
|
US7807822B2
(en)
|
1996-08-01 |
2010-10-05 |
Robert Bridenbaugh |
Methods for purifying nucleic acids
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
EP0853123A1
(de)
|
1997-01-10 |
1998-07-15 |
Roche Diagnostics GmbH |
Reinigung von DNA durch Cross-Flow-Filtration
|
JP2002508299A
(ja)
|
1997-09-19 |
2002-03-19 |
セクイター, インク. |
センスmRNA治療
|
US20020102563A1
(en)
|
1998-04-24 |
2002-08-01 |
Gjerde Douglas T. |
Apparatus and method for separating and purifying polynucleotides
|
WO2000075302A2
(en)
|
1999-04-30 |
2000-12-14 |
Cyclops Genome Sciences Limited |
Isolation of nucleic acid
|
BR0012627A
(pt)
|
1999-07-23 |
2002-04-09 |
Genentech Inc |
Processo para purificar o dna de plasmìdeo de células procarióticas mediante o emprego de filtração de fluxo tangencial
|
ES2238799T3
(es)
|
1999-09-09 |
2005-09-01 |
Curevac Gmbh |
Transferencia de arn-m.
|
WO2001046687A2
(en)
|
1999-12-22 |
2001-06-28 |
Transgenomic, Inc. |
System and method for automated matched ion polynucleotide chromatography
|
US6773885B1
(en)
*
|
2000-09-29 |
2004-08-10 |
Integrated Dna Technologies, Inc. |
Compositions and methods for visual ribonuclease detection assays
|
US7074333B2
(en)
|
2001-01-19 |
2006-07-11 |
Millipore Corporation |
Recovery of linear nucleic acids by salt dilution and/or reduced pressure prior to continuous pressure differential ultrafiltration
|
GB0107634D0
(en)
|
2001-03-27 |
2001-05-16 |
Fermentas Ab |
Nucleic acid purification
|
ATE376434T1
(de)
|
2001-04-21 |
2007-11-15 |
Curevac Gmbh |
Injektionsgerät für mrna applikation
|
EP2842964A1
(de)
|
2001-06-05 |
2015-03-04 |
Curevac GmbH |
Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
WO2003059381A2
(en)
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US6989442B2
(en)
|
2002-07-12 |
2006-01-24 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
DE10240868A1
(de)
|
2002-09-04 |
2004-03-18 |
Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH |
Verbesserte Verfahren zur Synthese von Nukleinsäuren
|
US7125492B2
(en)
|
2003-07-17 |
2006-10-24 |
Agilent Technologies, Inc. |
Additives for reversed-phase HPLC mobile phases
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
US8075780B2
(en)
|
2003-11-24 |
2011-12-13 |
Millipore Corporation |
Purification and concentration of synthetic biological molecules
|
WO2005058933A1
(en)
|
2003-12-16 |
2005-06-30 |
Gentra Systems, Inc. |
Formulations and methods for denaturing proteins
|
US20050287539A1
(en)
|
2004-06-29 |
2005-12-29 |
Emmanuel Labourier |
Methods and compositions for preparing capped RNA
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
JP4550115B2
(ja)
|
2004-08-03 |
2010-09-22 |
ジーンアート・アクチエンゲゼルシャフト |
CpG含量を変化させることにより遺伝子発現を調整する方法
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
CA2595594C
(en)
|
2005-01-31 |
2012-05-01 |
Merck & Co., Inc. |
Upstream and a downstream purification process for large scale production of plasmid dna
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
EP2311982A1
(en)
|
2005-12-12 |
2011-04-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Method of sequencing nucleic acids
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
JP2010507361A
(ja)
|
2006-07-31 |
2010-03-11 |
キュアバック ゲーエムベーハー |
具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
US7781573B2
(en)
|
2006-08-03 |
2010-08-24 |
Nam Q Ngo |
Multi layer chromatography of nucleic acids
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
US8859229B2
(en)
|
2007-02-02 |
2014-10-14 |
Yale University |
Transient transfection with RNA
|
GB0704352D0
(en)
|
2007-03-07 |
2007-04-11 |
Univ Belfast |
"Peptide, compositions and uses thereof"
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
PT2176408E
(pt)
|
2008-01-31 |
2015-04-23 |
Curevac Gmbh |
Ácidos nucleicos compreendendo a fórmula (nuglxmgnnv)a e os seus derivados como agentes/adjuvantes imunoestimuladores
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011056863A1
(en)
|
2009-11-03 |
2011-05-12 |
High Throughput Genomics, Inc. |
Quantitative nuclease protection sequencing (qnps)
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
WO2011069528A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Lyophilization of nucleic acids in lactate-containing solutions
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
US20130121998A1
(en)
|
2010-06-16 |
2013-05-16 |
Myra A. Lipes |
Diagnosis of Myocardial Autoimmunity in Heart Disease
|
DK2449113T3
(da)
|
2010-07-30 |
2016-01-11 |
Curevac Ag |
Kompleksdannelse af nukleinsyrer med disulfid-krydsbundne kationiske komponenter til transfektion og immunostimulering
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
DK3590949T3
(da)
|
2010-10-01 |
2022-07-11 |
Modernatx Inc |
Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
|
AU2011340132A1
(en)
|
2010-12-10 |
2013-05-02 |
Andrew Brian Herbert |
Compositions for separation methods
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
ES2742473T3
(es)
|
2012-03-27 |
2020-02-14 |
Curevac Ag |
Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos
|
WO2013143700A2
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
AU2013242403B2
(en)
|
2012-03-27 |
2018-10-18 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP2854857B1
(en)
|
2012-05-25 |
2018-11-28 |
CureVac AG |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
EP3884949A1
(en)
|
2012-06-08 |
2021-09-29 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
WO2014089486A1
(en)
|
2012-12-07 |
2014-06-12 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
WO2014149272A2
(en)
|
2013-02-14 |
2014-09-25 |
Tencate Advanced Armor Usa, Inc. |
Turret air bags
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
LT2970456T
(lt)
|
2013-03-14 |
2021-08-10 |
Translate Bio, Inc. |
Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
TR201903248T4
(tr)
|
2013-03-15 |
2019-03-21 |
Glaxosmithkline Biologicals Sa |
Rna saflaştırma yöntemleri.
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
RU2712743C2
(ru)
|
2013-08-21 |
2020-01-30 |
Куревак Аг |
Вакцина против бешенства
|
JP6678582B2
(ja)
|
2013-08-21 |
2020-04-08 |
キュアバック アーゲー |
肺癌処置のための組成物およびワクチン、組み合わせ、キット
|
BR112016000889A2
(pt)
|
2013-08-21 |
2017-12-12 |
Curevac Ag |
composição e vacina para tratamento de câncer de próstata
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
CN105451779A
(zh)
|
2013-08-21 |
2016-03-30 |
库瑞瓦格股份公司 |
增加rna编码蛋白表达的方法
|
WO2015024668A2
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Respiratory syncytial virus (rsv) vaccine
|
DE102013111099B4
(de)
*
|
2013-10-08 |
2023-11-30 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
RU2717986C2
(ru)
|
2013-12-30 |
2020-03-27 |
Куревак Аг |
Искусственные молекулы нуклеиновой кислоты
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
JP6584414B2
(ja)
|
2013-12-30 |
2019-10-02 |
キュアバック アーゲー |
人工核酸分子
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
EP3129050A2
(en)
|
2014-04-01 |
2017-02-15 |
CureVac AG |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
WO2015164773A1
(en)
|
2014-04-25 |
2015-10-29 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
EP3521456B1
(en)
|
2014-06-10 |
2023-01-04 |
CureVac Manufacturing GmbH |
Methods and means for enhancing rna production
|
EP4023755B1
(en)
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
US20170326225A1
(en)
|
2014-12-16 |
2017-11-16 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
MX2017008670A
(es)
|
2014-12-30 |
2017-10-11 |
Curevac Ag |
Moleculas artificiales de acido nucleico novedosas.
|
RS61531B1
(sr)
|
2015-04-13 |
2021-04-29 |
Five Prime Therapeutics Inc |
Kombinovana terapija za kancer
|
EP4353257A2
(en)
|
2015-04-13 |
2024-04-17 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
SG11201707832RA
(en)
|
2015-04-22 |
2017-11-29 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
WO2016174227A1
(en)
|
2015-04-30 |
2016-11-03 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
CN107889503A
(zh)
|
2015-04-30 |
2018-04-06 |
库瑞瓦格股份公司 |
固定化的聚(n)聚合酶
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
CN107873055B
(zh)
|
2015-05-29 |
2021-09-17 |
库瑞瓦格房地产有限公司 |
包括至少一个切向流过滤步骤的产生和纯化rna的方法
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
WO2017001058A1
(en)
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
EP3331555A1
(en)
|
2015-08-05 |
2018-06-13 |
CureVac AG |
Epidermal mrna vaccine
|
EP3332019B1
(en)
|
2015-08-07 |
2019-12-18 |
CureVac AG |
Process for the in vivo production of rna in a host cell
|
DE22195354T1
(de)
|
2015-08-10 |
2023-05-25 |
CureVac Manufacturing GmbH |
Verfahren zur erhöhung der replikation eines zirkulären dna-moleküls
|
WO2017036580A1
(en)
|
2015-08-28 |
2017-03-09 |
Curevac Ag |
Artificial nucleic acid molecules
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
WO2017081082A2
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Optimized nucleic acid molecules
|
WO2017108087A1
(en)
|
2015-12-21 |
2017-06-29 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
CN108778308A
(zh)
|
2015-12-22 |
2018-11-09 |
库瑞瓦格股份公司 |
生产rna分子组合物的方法
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
US20210180106A1
(en)
|
2016-02-12 |
2021-06-17 |
Curevac Ag |
Method for analyzing rna
|
WO2017140345A1
(en)
|
2016-02-15 |
2017-08-24 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
SG10201913630YA
(en)
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
EP3433361A1
(en)
|
2016-03-24 |
2019-01-30 |
CureVac AG |
Immobilized inorganic pyrophosphatase (ppase)
|
WO2017182634A1
(en)
|
2016-04-22 |
2017-10-26 |
Curevac Ag |
Rna encoding a tumor antigen
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
US11078247B2
(en)
|
2016-05-04 |
2021-08-03 |
Curevac Ag |
RNA encoding a therapeutic protein
|
US20210162037A1
(en)
|
2016-05-04 |
2021-06-03 |
Curevac Ag |
Influenza mrna vaccines
|
EP3464619A1
(en)
|
2016-05-25 |
2019-04-10 |
CureVac AG |
Novel biomarkers
|
KR20190029576A
(ko)
|
2016-06-09 |
2019-03-20 |
큐어백 아게 |
핵산 카고용 하이브리드 담체
|
EP3468609A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Cationic carriers for nucleic acid delivery
|
WO2017212006A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
US20190381180A1
(en)
|
2016-06-09 |
2019-12-19 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
SG10201913631TA
(en)
|
2016-08-19 |
2020-03-30 |
Curevac Ag |
Rna for cancer therapy
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
CN110582304A
(zh)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
用于治疗或预防肝脏疾病的rna
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
CN110392577A
(zh)
|
2017-03-17 |
2019-10-29 |
库尔维科公司 |
用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
|
CA3050616A1
(en)
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
CN111328287A
(zh)
|
2017-07-04 |
2020-06-23 |
库瑞瓦格股份公司 |
新型核酸分子
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
WO2019122371A1
(en)
|
2017-12-21 |
2019-06-27 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
BR112020020933A2
(pt)
|
2018-04-17 |
2021-04-06 |
Curevac Ag |
Moléculas de rna de rsv inovadoras e composições para vacinação
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
EP3814495B1
(en)
|
2018-06-28 |
2023-06-07 |
CureVac RNA Printer GmbH |
Bioreactor for rna in vitro transcription
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
US20220073962A1
(en)
|
2018-12-21 |
2022-03-10 |
Curevac Ag |
Methods for rna analysis
|
EP3920889A4
(en)
|
2019-02-08 |
2022-12-07 |
Board of Regents, The University of Texas System |
TELOMERASE-CONTAINING EXOSOMES FOR THE TREATMENT OF DISEASES RELATED TO AGE-RELATED ORGANDYS FUNCTION
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|